- Home
- LLY
as 09-17-2025 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 666.0B | IPO Year: | N/A |
| Target Price: | $972.00 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 15.29 | EPS Growth: | 88.31 |
| 52 Week Low/High: | $623.78 - $939.86 | Next Earning Date: | 10-29-2025 |
| Revenue: | $53,258,100,000 | Revenue Growth: | 36.83% |
| Revenue Growth (this year): | 38.29% | Revenue Growth (next year): | 18.33% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zakrowski Donald A | LLY | SVP, Finance, & CAO | Aug 28 '25 | Sell | $734.93 | 1,000 | $734,930.00 | 3,839.659 | |
| Montarce Lucas | LLY | EVP & CFO | Aug 15 '25 | Buy | $691.79 | 715 | $494,626.99 | 14,684.736 | |
| Van Naarden Jacob | LLY | EVP & Pres., Lilly Oncology | Aug 13 '25 | Buy | $647.36 | 1,000 | $647,360.00 | 20,561.985 | |
| Alvarez Ralph | LLY | N/A | Aug 13 '25 | Buy | $660.25 | 758 | $500,472.53 | 758 | |
| Sulzberger Gabrielle | LLY | N/A | Aug 12 '25 | Buy | $641.18 | 234 | $150,036.59 | 2,703.055 | |
| Skovronsky Daniel | LLY | EVP, CSO & Pres. LRL & LLY Imm | Aug 12 '25 | Buy | $634.41 | 2,000 | $1,268,810.00 | 137,660.112 | |
| Fyrwald J Erik | LLY | N/A | Aug 12 '25 | Buy | $642.29 | 3,130 | $2,010,484.70 | 74,577.779 | |
| Ricks David A | LLY | President, Chair, and CEO | Aug 12 '25 | Buy | $644.77 | 3,264 | $2,104,526.02 | 546,601.167 | |
| Yuffa Ilya | LLY | EVP&Pres, LLY USA&Global Capab | Aug 11 '25 | Sell | $627.01 | 2,500 | $1,567,525.00 | 26,259.971 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
The Fly
a day ago
Netflix upgraded, Five Below initiated: Wall Street's top analyst calls
MT Newswires
a day ago
Eli Lilly Says Late-Stage Trial of Weight Loss Drug Orforglipron Meets Primary, Secondary Endpoints
Benzinga
a day ago
Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?
PR Newswire
a day ago
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
MT Newswires
a day ago
Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats
Quartz
a day ago
Big Pharma flinches on Trump tariffsL Eli Lilly, GSK promise investment
Simply Wall St.
a day ago
Assessing Eli Lilly’s Valuation After Positive Obesity Drug Results and Major Virginia Facility Announcement
Pharmaceutical Technology
a day ago
Eli Lilly picks Virginia for $5bn drug manufacturing plant
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.